Human phagocyte flavocytochrome b 558 (Cyt b), the catalytic center of nicotinamide adenine dinucleotide phosphate oxidase, consists of a heavily glycosylated large subunit (gp91 phox ; Nox2) and a small subunit (p22 phox ). Cyt b is a membrane-spanning complex enzyme. Chronic granulomatous disease (CGD) is predominantly caused by a mutation in the CYBB gene encoding gp91 phox on the Xchromosome. Because the phagocytes of patients with CGD are not able to generate the superoxide anion, these patients are susceptible to severe infections that can be fatal. It has been suggested that the extracellular region of gp91 phox is necessary for and critical to forming the epitope of mAb 7D5 and that 7D5 provides a useful tool for rapid screening of X-linked CGD by FACS. To further elucidate the mAb 7D5 epitope on human gp91 phox , chimeric DNA expressed human and mouse gp91 phox recombinant protein were constructed. The fusion proteins were immunostained for mAb 7D5 and analyzed by FACS and western blot analysis. The 143 ELGDRQNES 151 region was found to reside at the extracellular surface on human gp91 phox and to be an important epitope for the interaction with mAb 7D5, as analyzed by FACS analysis. In particular, amino acid R147 is a unique epitope on the membrane-associated Cyt b for mAb 7D5. In conclusion, it is proposed that FACS analysis using mAb 7D5 is a valuable tool for early diagnosis of CGD.
Chronic granulomatous disease, an inherited disorder, is predominantly caused by a mutation in the CYBB gene encoding gp91
phox on the X-chromosome (1, 2). The phagocytes of CGD patients are unable to produce the superoxide anion via the NADPH oxidase complex enzyme (3) . Because phagocytes, including neutrophils, monocytes, macrophages and eosinophils, of patients with CGD (4-6) possess poor bactericidal activity, these individuals are susceptible to severe infections that can be fatal. The NADPH oxidase complex enzyme is an indispensable defense mechanism. Approximately 60% of patients with CGD have X-linked recessive CGD caused by mutations in the CYBB gene encoding gp91 phox (6) . Consequently, early diagnosis of this disease is crucial.
The NADPH oxidase complex enzyme comprises a membrane-spanning flavocytochrome b 558 (Cyt b) and cytosolic proteins p67 phox , p47 phox , p40 phox and Rac (5, (7) (8) (9) (10) (11) . In resting cells, p67
phox , p40 phox , p47 phox and Rac are present in the cytosol and the NADPH oxidase enzyme is inactive. Phagocytic neutrophils are activated by exposure to phagocytic microorganisms. After the cytosolic enzymes, p67
phox , p40 phox , p47 phox and Rac, have been transferred to the plasma membrane and combined with the Cyt b heterodimer, the NADPH oxidase complex enzyme generates O 2 À (2, 12). Cyt b, the catalytic center of NADPH oxidase, consists of two subunits: gp91 phox (a heavily glycosylated large bsubunit, Nox2) (1) and p22
phox (a small a-subunit) (13) . gp91
phox , a six-transmembrane protein containing two hemes in the N-terminus (14) (15) (16) , has five N-linked glycosylation sites (17) .
Studies characterizing the epitopes recognized by several mAbs against human Cyt b have reported that 54.1 (18) , NL7 (19) and 48 (20, 21) recognize the intracellular region of gp91 phox and that CL5 (22) and 7D5 (23) (24) (25) (24) . By contrast, our previous study suggested that the extracellular region of gp91 phox is necessary and sufficient to form the epitope for 7D5 (23, 25) . Although reported findings of both Burritt et al. and Yamauchi et al. have suggested that the mAb 7D5 epitope on human gp91
phox is located within the extracellular region, the precise position remained to be confirmed. Various experiments using mAbs, such as mAb NL7, have provided valuable further information regarding the structure and function of gp91 phox (9). Burritt and colleagues have reported that characterization of the oxidase inhibitory effects of mAb NL7 provides pertinent information on both the structural and mechanistic aspects of Cyt b function.
The aim of the present study was to determine the epitope on flavocytochrome b 558 recognized by mAb 7D5. Because mAb 7D5 does not detect the mouse gp91 phox protein, we used a transgenesis approach to construct human and mouse chimeric fusion proteins (25) . We then transfected the chimeric gene constructs into COS7 cell lines and detected the recombinant proteins by using anti-Cyt b mAb 7D5. To further elucidate the epitope of intact human gp91
phox , we compared the intact human or mouse proteins with the chimeric gp91 phox fusion protein for mAb 7D5 immunostaining by FACS analysis. We thus found that the 143 ELGDRQNES 151 region of the human gp91 phox protein is important and that a single amino acid, R147, is critical to the epitope recognized by mAb 7D5 and is a unique extracellular epitope on human gp91
phox . Accordingly, we propose that mAb 7D5 immunostaining by FACS analysis is a valuable tool for rapid diagnosis of CGD.
MATERIALS AND METHODS

Chemicals, reagents and materials
All general reagents of ultra-pure grade were obtained from Nacalai Tesque (Kyoto, Japan), Wako Pure Chemicals Industries (Tokyo, Japan) or Sigma-Aldrich Japan (Tokyo, Japan), unless otherwise stated. The reagents for gene recombination were obtained from NEB Japan (Tokyo, Japan) and pEGFP-C1 from Takara Bio (Shiga, Japan). Sense and anti-sense primers for PCR and sequencing primers were ordered from Sigma Genosys (Hokkaido, Japan) or Eurofins Genomics (Tokyo, Japan).
Antibodies
Anti-flavocytochrome b 558 mAb 7D5 was purchased from Medical and Biological Laboratories (Nagoya, Japan), anti-flavocytochrome b 558 NL7 from Santa Cruz Biotechnology (Dallas, TX, USA), mouse IgG1 iso-type control from BioSource International (Camarillo, CA, USA), purified mouse anti-gp91 phox for western blotting from BD Transduction Laboratories (Franklin Lakes, NJ, USA), anti-mouse IgG secondary antibody conjugated with Alexa Fluor 488 F (ab 0 ) 2 fragment from Thermo Fisher Scientific (Molecular Probes; Eugene, OR, USA), and anti-mouse IgG, HRP-linked F (ab 0 ) 2 fragment sheep antibody, ECL Advance and ECL Select from GE Healthcare (Chicago, IL, USA).
Cell lines
The myeloid leukemia cell line, HL-60, and mouse macrophage cell line, RAW264, were purchased from Riken Cell Bank (Tsukuba, Japan) and were grown in RPMI-1640 medium supplemented with 10% (v/v) FBS and 100 U/mL penicillin-100 mg/mL streptomycin at 37°C in an atmosphere of 5% CO 2 in air. The African green monkey kidney fibroblast-like cell line, COS7, was grown in D-MEM medium supplemented with 10% (v/ v) FBS and 100 U/mL penicillin-100 mg/mL streptomycin at 37°C in a 5% CO 2 atmosphere.
Construction of human and mouse gp91
phox chimeric gene A putative gp91 phox membrane-spanning model was predicted by using available web-based computational methods (TMpred [in-out], Mobyle portal, TOPCONS) (Table 1a ). The human gp91 phox amino acid sequence was obtained by using the default settings for each method. The final topology model of gp91 phox was roughly prepared manually by evaluation of both sets of computational results and several previously reported schematic models (6, 26, 27) (Table 1b) . For the chimeric gene constructs, a topology model was determined as shown in Table 1c . Subsequently, total human and mouse RNA was extracted from the cell lines HL60 and RAW264 and isolated by using an RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions, after which human and mouse fulllength first-strand gp91 phox cDNA was generated from the mRNA templates by using random primers (9) and Ready-To-Go You-Prime First-Strand Beads (GE Healthcare) according to the manufacturer's instruction. Human and mouse cDNA samples were amplified by PCR using KOD-Plus-ver.2 DNA polymerase (Toyobo, Osaka, Japan). The expected size of the amplified PCR product was 1700 bp, as analyzed on an agarose gel. Chimeric genes (Tables 2 and 3 ) were amplified by PCR using KOD-Plus-ver.2 DNA polymerase and then subcloned into modified mammalian expression vector pEGFP-C1. The EGFP gene was removed with restriction enzymes NheI and HindIII from pEGFP-C1 vector. The resultant full-length human, mouse or chimeric gene was then inserted into the vector with the restriction enzymes NheI and HindIII. These DNA ligation reactions were performed by using T4 DNA ligases (NEB Japan) or a Gibson Assembly Master Mix (NEB Japan) according to the manufacturer's instructions. Wild-type and chimeric construct plasmids were purified by using a QIAfilter Plasmid Midi Kit (Qiagen) and sequenced using an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems, Warrington, UK) and a BigDye Terminator Cycle Sequencing Kit ver.3.1 (Applied Biosystems, Foster City, CA, USA). FACS analysis was performed as described previously (25) . To prepare the cells, 1 Â 10 6 cells from the transfected cell lines were washed twice with PBS and then once in 500 mL of staining buffer (PBS containing 0.1% BSA, 0.5 mM ethylene glycol-bis baminoethyl ether tetra acetic acid and 10 mM NaN 3 ). Next, the cells were incubated with anti-gp91 phox 7D5 (final concentration 1 mg/mL) or mouse IgG1 iso-type control for 1 hr at room temperature. The cells were then washed twice with the staining buffer, after which they were incubated with anti-mouse IgG secondary antibody conjugated with Alexa Fluor 488 F (ab 0 ) 2 fragment (final concentration 1 mg/mL) for 1 hr at room temperature in the dark. The cells were then washed twice with the staining buffer. Flow cytometry was performed on a FACSCanto II instrument (Becton Dickinson, Franklin Lakes, NJ, USA). FACS data analysis was performed by using Flow Jo software (Flow Jo LLC, Ashland, OR, USA).
Expression
Purification of the GST fusion gp91 phox C-terminal 384-570 aa fragment proteins
The human gp91
phox C-terminal 384-570 aa fragment and mouse gp91
phox C-terminal 384-570 aa fragment were transformed into the pET-42a system, which was designed for the cloning and high-level expression of GST-Tag proteins. The recombinant expression proteins were purified by affinity purification on glutathione sepharose 4B (GE Healthcare). The purified fusion proteins were quantified by using a DC protein assay (Bio-Rad, Hercules, CA, USA). The purities of recombinant proteins were confirmed by SDS-PAGE and CBB staining.
Western blot analysis
The recombinant human, mouse and chimeric gp91 phox proteins expressed in COS7 cells were prepared for SDS-PAGE by a trichloroacetic acid method. Following SDS-PAGE, western blotting was performed using the purified mouse anti-gp91[phox] antibody (BD). Western blotting of the recombinant human and mouse GST fusion proteins was performed using the purified mouse anti-gp91[phox] antibody (BD) and then the human mAb NL7 (SC) after stripping the former antibody. Specific bands probed with the antibodies were visualized by using Amersham ECL Prime to detect chemiluminescence.
RESULTS
Design and construction of human and mouse gp91 phox chimeric genes
It has previously been reported that the gp91 phox mAb 7D5 epitope is located on the extracellular domain of Cyt b (24, 25) . To clarify the precise location of the epitope, human and mouse gp91 phox chimeric genes were constructed by substituting mouse gp91 phox extracellular amino acids for those in the human construct on the basis of our previous observation that mAb 7D5 recognizes human gp91 phox but not mouse gp91 phox (25) . Figure 1 shows a schematic model of human and mouse putative gp91 phox (6, 17, 21, 26, 27 ) containing cytosolic domains IC1-IC4, transmembrane domains TM1-TM6 and extracellular domains EC1-EC3. Human gp91 phox and mouse gp91 phox comprises the same number of amino acids (570). A topology model of gp91 phox (Table 1c) was prepared manually by evaluation of both computational results and several schematic models reported previously (6, 26, 27) (Table 1b) . Putative transmembrane a-helices on human gp91 phox were predicted by using available web-based computational methods (TMpred [in-out], Mobyle portal and TOPCONS) (Table 1a) .
Initially, human and mouse gp91 phox cDNA were generated from mRNA templates. Human and mouse cDNAs and a number of chimeric gene constructs were amplified by PCR. The chimeric protein constructs were then analyzed; some of these data are shown in Table 2 (C1-C15). Mouse extracellular domain nucleotides (EC1, EC2, EC3; yellow highlighting) were substituted for human DNA. The extracellular EC1, EC2 and EC3 domains were constructed by a single substitution (Table 2 ; C4, C6, C8) or a combination of mutations (Table 2 ; C9-C12). Conversely, in the C15 construct, only the EC2 domain of mouse gp91
phox was substituted with the human sequence. All chimeric transgenic constructs were sequenced to confirm their alignments. 
Human and mouse consensus sequences are shown in black, human-specific amino acids in red and mouse-specific amino acids in bold blue font. þ, mAb 7D5 recognizes the chimeric construct; À, mAb 7D5 does not recognize the chimeric construct. 
The domain names (IC1, TM1 and EC1) correspond with those in Figure 1 . Table 2 , FACS data are shown in Fig. 2a ), but not mouse gp91 phox (mouse cybb in Table 2 , FACS data are shown in Fig. 2e ). Chimeric constructs (C6, C9, C11, C12) containing mouse-type amino acids in the EC2 domain were not recognized by mAb 7D5 (Table 2 , FACS data not shown). By contrast, chimeric constructs (C4, C8, C10) containing mouse-type amino acids in the EC1 and EC3 domains were recognized by mAb 7D5, similarly to intact human protein ( Table 2 , FACS data not shown). As shown in Table 2 , only the constructs containing human-type amino acids in the EC2 domain were recognized by mAb 7D5 (Table 2 ) (23, 25) . These results indicate that the mAb 7D5 epitope exists in the EC2 domain.
To more precisely map the mAb 7D5 epitope in the human EC2 domain (124-169 amino acids), all or some parts of this domain were substituted with mouse amino acids (Fig. 1) . The EC2 domain was partitioned into four regions, namely, EC2-1, EC2-2, EC2-3 and EC2-4 ( Fig. 1 and Table 3 ) and these four regions substituted with mouse-type amino acids. These constructs were transfected in COS7 cells and the expressed proteins stained with mAb 7D5. FACS analysis revealed that, although the EC2-1, EC2-3 and EC2-4 regions had been substituted with mouse amino acids, these fusion proteins were still recognized by mAb 7D5. In contrast, the protein in which the EC2-2 region had been substituted with mouse amino acids was not recognized by mAb 7D5 (Table 3 and Fig. 2b) . These results suggest that the EC2-2 region containing amino acids 143 ELGDRQNES 151 on human gp91 phox is essential for recognition of the epitope by mAb 7D5 (Table 3) .
To further elucidate the 143 ELGDRQNES 151 region in human gp91
phox , a series of amino acid substitutions was constructed, as shown in Table 4 . Five distinct amino acids in the human sequence were compared with those in the mouse sequence: E143, L144, R147, Q148 and S151. These five amino acids on human gp91
phox were systematically replaced with those in mouse gp91
phox . As shown in Table 4 , the constructs in numbers 2-8 were phox protein The final topology model of human gp91 phox was generated by three computational analyses that are described in the Materials and Methods as well as from previously reported experimental data (6, 26, 27) . As shown in the figure, EC1-EC3 are gp91 phox extracellular domains, TM1-TM6 transmembrane regions and IC1-IC4 cytosolic domains. In addition, EC2 is subdivided into four small regions, EC2-1-EC2-4. Human and mouse amino acids for EC2 (124-169 aa) are shown with the consensus sequence in black, human-specific amino acids in red, and mouse-specific amino acids in blue. The carboxyl terminal (COOH) and amino terminal (NH 2 ) ends are indicated.
substituted for five amino acids from the 143 to 151 region on human gp91 phox , whereas the constructs in numbers 10-24 were substituted for five amino acids from the 143 to 151 region on mouse gp91
phox . When a single amino acid R147 was substituted by N147 in the total human gp91 phox (Fig. 2c ) or in the partial chimeric protein m(EC2-2)h, R147N (Fig. 2f) Table 4 , the number 8 constructs (Fig. 2d) (Table 4 and Fig. 2g ) indicated that N147 in the full length mouse amino acids had been substituted by R147. The both resulting expression protein kept the interaction with mAb 7D5. Although constructs number 8 and 11 (Table 4 and Fig. 2d, g ) comprised different types of amino acids, R147N was the only identical substitution in both of these constructs. Thus, when the amino acid R147 was present in the EC2-2 region, gp91 phox expression protein gained the ability to recognize mAb 7D5 (Fig. 2d,g ). Furthermore, when E143 or I144 and R147 and S151 were present in the EC2-2 region, these expression proteins were more strongly recognized by mAb 7D5 (Table 4, number 19 and 20 7D5; FACS data not shown). Moreover, when all five amino acids in mouse gp91 phox had been changed to the human-type amino acids, the resultant chimeric mouse gp91 phox expression protein was recognized by mAb 7D5 similarly to the human gp91 phox expression protein (Table 4 , number 24 and Fig. 2h ). These results demonstrate that the R147 amino acid on human gp91
phox is essential for epitope formation and E143, L144, Q148 and S151 support the epitope in FACS analysis using mAb 7D5.
Western blot analysis of human and mouse gp91 phox expressed in COS7 cells
Mouse recombinant expression protein is not recognized by mAb 7D5 (Fig. 2e) . To determine whether mouse recombinant protein is expressed properly in 
To investigate the EC2-2 region 143 ELGDRQNES 151 on human gp91 phox , we constructed various amino acids substitutions. Human and mouse consensus sequences are shown by dots, human-specific amino acids are in red and mouse-specific amino acids in blue. In number 2-8 chimeric constructs some amino acids of human gp91 phox were substituted for the mouse sequence 9, whereas in number 10-24 chimeric constructs some amino acids of mouse gp91 phox amino acids were substituted for the human sequence. The chimeric constructs were transfected into COS7 cells, and the expressed proteins were immunostained for FACS analysis as described in the Materials and Methods. FACS analysis results are on the right side of the table. h(E143D, L144I)m represents the 143rd human amino acids, E, which is substituted by D, and the 144th human amino acids, L, which is substituted by I. þþþþ, mAb 7D5 recognizes both chimeric constructs and intact human gp91 phox approximately equally; þþþ and þþ, mAb 7D5 recognizes chimeric constructs slightly and significantly lower than intact human gp91 phox respectively; þ, mAb 7D5 barely recognizes chimeric constructs; and À, mAb 7D5 does not recognize chimeric constructs. Letters a-h correspond to the FACS analysis results in panels a-h in Figure 2 .
COS7 cells, the human and mouse chimeric proteins expressed in COS7 cells were confirmed by western blot analysis with another Ab raised against c-terminal antigen (450-556 aa) of gp91 phox (Fig. 3) . The chimeric proteins were recognized similarly by the antibodies to human and mouse gp91 phox (lanes 1 and 5), indicating that recombinant mouse gp91 phox proteins are not recognized by mAb 7D5, not because of the amount of expression protein, but rather because of the distinct amino acids within the mAb 7D5 epitope region of the gp91 phox protein.
Western blot analysis of the purified GST fusion gp91 phox C-terminal 384-570 aa fragment protein
In addition, experiments were performed to determine if there were any differences in protein expressions of human and mouse gp91
phox . GST fusion constructs for the gp91 phox C-terminal 384-570 aa fragments of human and mouse gp91
phox were constructed and transformed by using the pET-42a system, which had been designed for cloning and high-level expression of peptide sequences, fused with the 220 aa GST- Tag   TM protein. The recombinant expression proteins were affinity purified by using glutathione sepharose 4B and then examined by 10% SDS-PAGE. The human and mouse fusion protein had an apparent molecular weight of 56,400 Da, and only a single band was identified on CBB staining (Fig. 4a) . The human gp91 phox recombinant fusion protein was comparable with the mouse protein according to western blot analysis (Fig. 4b, c) . The GST-fused human and mouse gp91 phox C-terminal proteins were stained with gp91 phox antibody (BD), the immunogen being mouse gp91 phox aa 450-556 (Fig. 4b) and the anti-human gp91 phox mAb NL7 epitope 498 EKDVITGLKQ 507 (19) (Fig. 4c) . The epitope on both antibodies was found to be present in the cytosolic domain IC4 (Fig. 1) . Immunostaining using both antibodies indicated that there is no difference in strength of protein expression between human and mouse gp91 phox in our experimental system. phox C-terminal 384-570 aa fragments were transformed using the pET-42a system. The recombinant proteins were affinity purified using glutathione sepharose 4B, then loaded equally onto SDS-PAGE and detected by chemiluminescence. (a) After SDS-PAGE, the polyacrylamide gel was stained with CBB; (b) western blotting revealed that the first Ab was anti-gp91 phox (BD) (mouse 450-556aa)
(1:2000) and the second anti-mouse-HRP (1:100,000); (c) western blotting revealed that the first Ab was mAb NL7 (human 498-507aa) (1:1000) and the second anti-mouse-HRP (1:50,000). 
DISCUSSION
In this study, we examined the mAb 7D5 epitope of human gp91 phox in greater detail than has hitherto been reported. The epitope is reportedly roughly presented on the surface of neutrophils, eosinophils, monocytes/ macrophages and B-lymphocytes (23, 28) . We deduced the putative structure of gp91 phox (Fig. 1, Table 1c ) from nucleotide sequences by computational analysis (Table 1a ) and a previously reported topology model (Table 1b) (6, 26, 27) and then constructed an array of chimeric proteins of human and mouse gp91 phox , as shown in Table 2 . When the extracellular domain (EC2, (Fig. 1, Table 1 ). In the present study, we found that the extracellular EC2 domain is recognized by mAb 7D5, regardless of whether the extracellular EC3 domain comprised human or mouse amino acids (Table 2 ). Burritt and colleagues' experimental approach employed phage display epitope mapping, whereas we used gene recombination techniques to investigate the effects of amino acids in the gp91 phox extracellular domain (Tables 2 and 3 ). Furthermore, we examined the impact of each of five amino acids, E143, L144, R147, Q148 and S151, in the EC2 domain (Tables 3 and 4) on mAb 7D5 recognition. We found that when amino acid R147 is absent from EC2-2, gp91
phox is not quite recognized by mAb 7D5, whereas when amino acid R147 is present in the EC2-2 region, gp91
phox gains the ability to recognize mAb 7D5. These findings indicate that amino acid R147 on human gp91 phox alone is essential for and critical to FACS detection with mAb 7D5 (Table 4 , Fig. 2 ). We found that more than three amino acid substitutions in five amino acids approximate to the intensity of intact human gp91 phox (Table 4 , numbers 19-23). As the amino acid substitution rate in the four amino acids (E143, I144, Q148 and S151) increases, these chimeric expression proteins are recognized more strongly by mAb 7D5. Finally, when the five amino acids (E143, L144, R147, Q148 and S151) are all present in the gp91 phox EC2-2, the chimeric expression protein is recognized at a similar level to human gp91 phox (Table 4 , number 24, Fig. 2h ). Although R147 single substitution is insufficient for full recognition by 7D5, the amino acid R147 is essential and critical. Additionally, the amino acids E143, L144, Q148 and S151 support the epitope in FACS detection with mAb 7D5.
To determine whether the strength of expression of mouse recombinant protein was responsible for our findings, we analyzed the human and mouse chimeric proteins expressed in COS7 cells by western blot analysis (Fig. 3) (Fig. 3) . In other words, the mouse protein expressed in COS7 cells was about tenfold greater than the human gp91 phox protein in COS7 cells because the cells/lanes differed between human and mouse. We were therefore able to exclude the possibility that insufficient protein expression resulting in undetectable amounts in FACS analysis explains the fact that recombinant mouse gp91 phox protein in COS7 was not recognized by mAb 7D5. The apparent molecular weight of recombinant human gp91 phox expressed in COS7 cells differs from that of mouse gp91 phox and human peripheral neutrophils. Because intact human gp91 phox protein is a glycosylated protein (17) , it is possible that native human neutrophils and recombinant human and mouse gp91 phox proteins exist in different glycosylation states. SDS-PAGE and western blot analysis of the purified GST fusion proteins of the gp91 phox C-terminal 384-570 aa fragments (Fig. 4 ) revealed that the recombinant human and mouse gp91 phox protein were expressed approximately equally and the affinity of the antibody for gp91 phox protein was approximately equal in human and mouse. Therefore, the results of the COS7 expression protein western blots (Fig. 3) indicate that the differences in the bands of human and mouse gp91 phox are reflected by quantity of full-length gp91 phox protein expression in COS7, not by the affinity of the antibody for protein.
Burritt and colleagues have previously reported that mAb CL5 is specific for the large subunit of b 558 and that the CL5 epitope contains the 135 -DPYSVALSELGDR region of gp91 phox (22 Fig. 2c ) is not recognized with mAb 7D5, the protein is revealed by western blotting with mAb CL5 (data not shown). Accordingly, it is likely that the epitopes of mAb 7D5 and mAb CL5 differ. Certainly, analysis of a mAb can reveal structure-function relationships that provide necessary information about molecular mechanisms (20, 28) . Therefore, we propose that it is essential to clarify the epitope for this mAb 7D5. We also hope that in the future the epitope of mAb CL5 will be studied in detail.
CGD, which is caused by phagocytes defective in superoxide-producing activity (29) , is a rare genetic syndrome with an incidence of between 1 in 200,000 and 1 in 250,000 worldwide (30) . gp91
phox (Nox2) is a functional domain of the NADPH oxidase activation system. As Roos et al. have reported, X-linked CGD is caused by a great variety of mutations, including deletions, splice site mutations and missense or nonsense mutations (6, 31, 32) . Early diagnosis of CGD is vital for appropriate therapeutic care and improving prognosis (33). Hawary and colleagues have reported using flow cytometry with dihydrorhodamine 123 to analyze NADPH components in patients diagnosed as having CGD and their results have been confirmed by targeted Sanger sequencing (33) . We propose immunostaining the phagocytes of patients with CGD with mAb 7D5 and dihydrorhodamine 123, analyzing them by flow cytometry and sequencing these patients' genomes. Previously, Yamauchi et al. reported that localizing the epitope on gp91 phox would increase its reliability for use in diagnosis and monitoring of gene therapy for X-linked CGD (25) . Our findings provide new insights into the epitope of human gp91 phox recognized by mAb 7D5 and illustrate the potential for FACS analysis using mAb 7D5 as a tool for diagnosing CGD.
